Source comparison
SS-31 vs MOTS-C: Published Research Highlights
The published literature on SS-31 vs MOTS-C spans different therapeutic areas, reflecting their mechanistic divergence. For SS-31, the SPARCL trial (2019, n=36) investigated elamipretide in patients with Barth syndrome over 36 weeks, demonstrating statisticall
This comparison does not assign a generated winner or score.
- The published literature on SS-31 vs MOTS-C spans different therapeutic areas, reflecting their mechanistic divergence. For SS-31, the SPARCL trial (2019, n=36) investigated elamipretide in patients with Barth syndrome over 36 weeks, demonstrating statistically significant improvements in the 6-minute walk test and left ventricular mass index.
- The MMPOWER trial examined SS-31 in mitochondrial myopathy patients across 40 sites, with 72.7% of participants showing improvement in fatigue scores versus 32% in placebo — a difference attributable directly to improved mitochondrial ETC efficiency. The FDA’s 2023 accelerated approval of elamipretide for Barth syndrome marked a historic milestone as the first approved mitochondria-targeted peptide therapy.
- For MOTS-C research, investigators have focused primarily on metabolic disease and aging models. A 2019 study in Nature Communications found that exogenous MOTS-C administration in aged mice (20 months) improved physical performance on grip strength and treadmill tests by 15–20% after 4 weeks, with corresponding improvements in muscle mitochondrial density.
- A 2022 human observational study (n=47) identified circulating MOTS-C as an independent predictor of insulin resistance (OR 2.3, 95% CI 1.1–4.8), lending clinical relevance to mechanistic animal findings. Researchers studying the SS-31 vs MOTS-C landscape note that the two compounds have rarely been tested head-to-head, as their mechanisms are sufficiently distinct that direct comparison is less meaningful than choosing based on research focus.